Trial Profile
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Progenics Pharmaceuticals
- 22 Dec 2021 According to Bausch Health Companies media release, results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in The Journal of Emergency Medicine
- 22 Dec 2021 Results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in the Bausch Health Companies Media Release
- 22 Dec 2021 According to Bausch Health Companies media release, data from a post-hoc analysis (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) supports the use of Salix s RELISTOR for patients with Opioid-Induced Constipation and advanced illness in the Emergency Department Setting